enGene
Yulin Wang has extensive experience in process development and research within the pharmaceutical and materials science industries. Currently serving as Process Development Manager at enGene since August 2019, Yulin Wang leads CMC activities for drug substance and product development aimed at supporting BLA submissions. Prior experience includes roles at Interface Biologics, where Yulin Wang progressed from Research Chemist I to Senior Research Associate, overseeing formulation development and managing in vivo trial processes. Additional positions include Optical Lab Technician at P&P Optica, R&D Lab Technician at Mascoma Corp., and Graduate Research Assistant at the University of Waterloo, where Yulin Wang gained expertise in polymer synthesis and characterization. Yulin Wang holds a Master of Science in Polymer Chemistry and dual Bachelor’s degrees in Chemistry and Applied Chemistry.
This person is not in any teams
enGene
enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA (siRNA, shRNA, lncRNA etc.) with broad tissue and disease applications